Key facts
- Metis TechBio and Eli Lilly agreed to collaborate on drug delivery technologies.
- The deal could be worth as much as $1.1 billion.
- Metis TechBio is listed in Hong Kong.
Hong Kong-listed Metis TechBio announced on Monday, October 19, that it has entered into a collaboration agreement with Eli Lilly. The deal focuses on the research and development of tissue-specific drug delivery technologies. The agreement has a potential value of up to $1.1 billion.